Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31541474 | 0.80 | ALDH1A1 (0.41) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1570052 | 0.80 | MAPT (0.37) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL28684618 | 0.80 | NPC1 (0.46) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL28932271 | 0.80 | NPC1 (0.50) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL31541475 | 0.80 | ALDH1A1 (0.41) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL11719543 | 0.78 | PDE3B (0.49) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL28703819 | 0.78 | CHRNB4 (0.45) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL28677904 | 0.78 | PDE3B (0.51) | PDE3BPDE3APTGS1CHRNB4CHRNA3 | |
| SCHEMBL28687865 | 0.78 | CHRNB4 (0.45) | MAPTKDM4ENPC1RAB9AKMT2A | |
| SCHEMBL28677905 | 0.78 | PDE3B (0.49) | MAPTALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119404851-A | Antibacterial application of indolizine-spiro-oxazolinone compound | 青岛农业大学 | 2025-02-11 | — | — | CN | claimed |
| CN-118393827-A | High-temperature-resistant low-corrosion photoresist stripping liquid and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-119404851-A | Antibacterial application of indolizine-spiro-oxazolinone compound | 青岛农业大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-118393827-A | High-temperature-resistant low-corrosion photoresist stripping liquid and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-113999131-B | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-113999131-A | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-02-01 | — | — | CN | disclosed |
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-16 | — | — | US | disclosed |
| US-9796675-B1 | Intermediate for synthesizing paroxetine, method for preparing the same, and uses thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2017-10-24 | — | — | US | disclosed |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170283380-A1 | Intermediate for Synthesizing Paroxetine, Method for Preparing the same, and Uses Thereof | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2017-10-05 | — | — | US | disclosed |
| EP-3199526-A1 | INTERMEDIATE FOR USE IN SYNTHESIZING PAROXETINE, PREPARATION METHOD FOR THE INTERMEDIATE, AND USES THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd (CN) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016016865-A1 | A PROCESS FOR THE PREPARATION OF NUCLEOSIDE PHOSPHORAMIDATE | LUPIN LIMITED (IN) | 2016-02-04 | — | — | WO | disclosed |
| EP-0859766-B1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AG (DE) | 2001-05-16 | — | — | EP | disclosed |
| EP-0859766-A1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997015561-A1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | PAM, PDXK, GRHPR | MAPT 2753/4885ALDH1A1 1647/4885KDM4E 377/4885 |
| US-20170283380-A1 | Intermediate for Synthesizing Paroxetine, Method for Preparing the same, and Uses Thereof | TPH2, TPH1, HTR1F | MAPT 3006/4885ALDH1A1 1943/4885KDM4E 1638/4885 |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | TDO2, HPD, PDXK | MAPT 3185/4885ALDH1A1 879/4885KDM4E 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.